How should I evaluate and manage an 18‑year‑old woman taking Nylia (ethinyl estradiol/levonorgestrel) 7/7/7 for one year who has had three months of continuous vaginal bleeding accompanied by light‑headedness, dizziness, and low energy?

Immediate Evaluation and Management of Prolonged Breakthrough Bleeding on Combined Oral Contraceptives

This 18-year-old requires urgent evaluation for anemia given her symptoms of lightheadedness, dizziness, and low energy after 3 months of continuous bleeding, followed by immediate treatment with NSAIDs and consideration of switching from her triphasic to a monophasic combined oral contraceptive regimen. 1

Urgent Initial Assessment

Check hemoglobin/hematocrit immediately to assess for anemia, as her symptoms of lightheadedness, dizziness, and low energy strongly suggest significant blood loss requiring urgent intervention. 1

Before treating the bleeding, you must rule out:

• Pregnancy (urine or serum β-hCG test) 1
• Sexually transmitted infections (cervical testing for chlamydia and gonorrhea) 1
• Thyroid dysfunction (TSH level) 1
• New uterine pathology such as polyps or fibroids (transvaginal ultrasound if clinically indicated) 1
• Medication interactions or non-adherence 1

Immediate Treatment Strategy

First-Line Intervention: NSAIDs

Start ibuprofen 400-600 mg three times daily for 5-7 days as the initial treatment for breakthrough bleeding while continuing the current contraceptive. 1 This approach addresses the bleeding without requiring immediate method discontinuation and allows time for diagnostic workup.

Critical Problem with Current Regimen

Nylia 7/7/7 is a triphasic formulation that provides varying hormone doses throughout the cycle, which increases breakthrough bleeding risk compared to monophasic pills. 2 The CDC specifically recommends monophasic combined oral contraceptives containing 30-35 μg ethinyl estradiol for managing menstrual irregularities. 2

Definitive Management Plan

Switch to Monophasic Formulation

After completing the NSAID course, transition her to a monophasic combined oral contraceptive containing 30-35 μg ethinyl estradiol with levonorgestrel or norgestimate (such as standard Seasonale or a monophasic 28-day formulation). 2 This provides:

• More stable hormone levels throughout the cycle 2
• Better endometrial suppression 2
• Reduced breakthrough bleeding over time 3, 4, 5

Transition Protocol

• Complete the current pill pack of Nylia 1
• Start the new monophasic formulation immediately the next day without a hormone-free interval 1
• No backup contraception is needed when switching between combined hormonal contraceptives 6
• Counsel that breakthrough bleeding may persist for 3-6 months but typically decreases with continued use 1, 3

Management of Anemia (If Present)

If hemoglobin is low:

• Start oral iron supplementation (ferrous sulfate 325 mg daily or as tolerated) 1
• Consider extended or continuous regimen (84 days active pills followed by 7-day hormone-free interval) to reduce total menstrual blood loss 2, 7
• Recheck hemoglobin in 4-6 weeks to ensure recovery 1

If Initial Treatment Fails

Second-Line Options (if NSAIDs ineffective after 5-7 days):

1. Allow a planned 3-4 day hormone-free interval to induce withdrawal bleeding and thin the endometrium, but not during the first 21 days of the new regimen and not more than once per month 1, 2
2. Add a short course of additional estrogen (10-20 days of low-dose combined oral contraceptives or estrogen alone) 1
3. Consider tranexamic acid 1300 mg three times daily for 5 days during bleeding episodes 1

Third-Line: Method Change

If bleeding persists despite the above interventions:

• Consider switching to a levonorgestrel-releasing IUD, which achieves 50% amenorrhea rates within 2 years and reduces menstrual blood loss by 71-95% 2, 6
• Alternative: depot medroxyprogesterone acetate (DMPA) 150 mg intramuscularly every 12 weeks, though this causes irregular bleeding initially before eventual amenorrhea 2, 6

Critical Counseling Points

Reassure the patient that breakthrough bleeding with combined oral contraceptives is common during the first 3-6 months and does not indicate method failure or harm. 1, 3 However, 3 months of continuous bleeding warrants intervention.

Emphasize that switching to a monophasic formulation will likely improve her bleeding pattern within 1-3 cycles, with progressive improvement over time. 3, 4, 5, 7

Counsel about missed pill management: If she misses one pill, take it immediately and continue as scheduled; if she misses two or more pills, take the most recent missed pill, use backup contraception for 7 days, and consider emergency contraception if unprotected intercourse occurred in the prior 5 days. 2

Common Pitfalls to Avoid

• Do not discontinue the contraceptive without offering treatment options first, as many women discontinue effective contraception unnecessarily due to manageable bleeding 1
• Do not ignore symptoms of anemia—lightheadedness, dizziness, and low energy after 3 months of bleeding mandate hemoglobin assessment 1
• Do not continue a triphasic formulation when breakthrough bleeding is problematic—monophasic pills provide superior cycle control 2
• Do not allow hormone-free intervals more than once per month, as this reduces contraceptive effectiveness 1, 2